FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938397237> ?p ?o ?g. }

• W2938397237 endingPage "107597" @default.
• W2938397237 startingPage "107597" @default.
• W2938397237 abstract "Prescription opioid abuse is a global crisis. New treatment strategies for pain and opioid use disorders are urgently required. We evaluated the effects of R-VK4-40, a highly selective dopamine (DA) D3 receptor (D3R) antagonist, on the rewarding and analgesic effects of oxycodone, the most commonly abused prescription opioid, in rats and mice. Systemic administration of R-VK4-40 dose-dependently inhibited oxycodone self-administration and shifted oxycodone dose-response curves downward in rats. Pretreatment with R-VK4-40 also dose-dependently lowered break-points for oxycodone under a progressive-ratio schedule. To determine whether a DA-dependent mechanism underlies the impact of D3 antagonism in reducing opioid reward, we used optogenetic approaches to examine intracranial self-stimulation (ICSS) maintained by optical activation of ventral tegmental area (VTA) DA neurons in DAT-Cre mice. Photoactivation of VTA DA in non-drug treated mice produced robust ICSS behavior. Lower doses of oxycodone enhanced, while higher doses inhibited, optical ICSS. Pretreatment with R-VK4-40 blocked oxycodone-enhanced brain-stimulation reward. By itself, R-VK4-40 produced a modest dose-dependent reduction in optical ICSS. Pretreatment with R-VK4-40 did not compromise the antinociceptive effects of oxycodone in rats, and R-VK4-40 alone produced mild antinociceptive effects without altering open-field locomotion or rotarod locomotor performance. Together, these findings suggest R-VK4-40 may permit a lower dose of prescription opioids for pain management, potentially mitigating tolerance and dependence, while diminishing reward potency. Hence, development of R-VK4-40 as a therapy for the treatment of opioid use disorders and/or pain is currently underway. This article is part of the Special Issue entitled ‘New Vistas in Opioid Pharmacology’." @default.
• W2938397237 created "2019-04-25" @default.
• W2938397237 creator A5004234860 @default.
• W2938397237 creator A5006854305 @default.
• W2938397237 creator A5010869299 @default.
• W2938397237 creator A5019199940 @default.
• W2938397237 creator A5023686004 @default.
• W2938397237 creator A5060050668 @default.
• W2938397237 creator A5061926206 @default.
• W2938397237 creator A5064024738 @default.
• W2938397237 creator A5065836423 @default.
• W2938397237 creator A5071244438 @default.
• W2938397237 creator A5083774896 @default.
• W2938397237 creator A5086915181 @default.
• W2938397237 creator A5090359406 @default.
• W2938397237 date "2019-11-01" @default.
• W2938397237 modified "2023-10-12" @default.
• W2938397237 title "The highly selective dopamine D R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents" @default.
• W2938397237 cites W1028908987 @default.
• W2938397237 cites W1481581387 @default.
• W2938397237 cites W1482965181 @default.
• W2938397237 cites W1766653312 @default.
• W2938397237 cites W1964600015 @default.
• W2938397237 cites W1974681763 @default.
• W2938397237 cites W1978999141 @default.
• W2938397237 cites W1979129023 @default.
• W2938397237 cites W1988659186 @default.
• W2938397237 cites W1997132021 @default.
• W2938397237 cites W2006581907 @default.
• W2938397237 cites W2007236389 @default.
• W2938397237 cites W2012111567 @default.
• W2938397237 cites W2013159064 @default.
• W2938397237 cites W2016794146 @default.
• W2938397237 cites W2028345823 @default.
• W2938397237 cites W2035275729 @default.
• W2938397237 cites W2035419353 @default.
• W2938397237 cites W2037899693 @default.
• W2938397237 cites W2042360484 @default.
• W2938397237 cites W2052001699 @default.
• W2938397237 cites W2052495267 @default.
• W2938397237 cites W2053749722 @default.
• W2938397237 cites W2057518027 @default.
• W2938397237 cites W2059111839 @default.
• W2938397237 cites W2072724153 @default.
• W2938397237 cites W2074607412 @default.
• W2938397237 cites W2079086643 @default.
• W2938397237 cites W2083294529 @default.
• W2938397237 cites W2094340385 @default.
• W2938397237 cites W2100963192 @default.
• W2938397237 cites W2148455827 @default.
• W2938397237 cites W2148874230 @default.
• W2938397237 cites W2157312676 @default.
• W2938397237 cites W2162621138 @default.
• W2938397237 cites W2164388519 @default.
• W2938397237 cites W2166060597 @default.
• W2938397237 cites W2323221475 @default.
• W2938397237 cites W2404186171 @default.
• W2938397237 cites W2461901476 @default.
• W2938397237 cites W2509180953 @default.
• W2938397237 cites W2528026532 @default.
• W2938397237 cites W2586914431 @default.
• W2938397237 cites W2609711934 @default.
• W2938397237 cites W2611268510 @default.
• W2938397237 cites W2752805271 @default.
• W2938397237 cites W2755190328 @default.
• W2938397237 cites W2800878103 @default.
• W2938397237 cites W2888434368 @default.
• W2938397237 doi "https://doi.org/10.1016/j.neuropharm.2019.04.003" @default.
• W2938397237 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6745270" @default.
• W2938397237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30974107" @default.
• W2938397237 hasPublicationYear "2019" @default.
• W2938397237 type Work @default.
• W2938397237 sameAs 2938397237 @default.
• W2938397237 citedByCount "47" @default.
• W2938397237 countsByYear W29383972372018 @default.
• W2938397237 countsByYear W29383972372019 @default.
• W2938397237 countsByYear W29383972372020 @default.
• W2938397237 countsByYear W29383972372021 @default.
• W2938397237 countsByYear W29383972372022 @default.
• W2938397237 countsByYear W29383972372023 @default.
• W2938397237 crossrefType "journal-article" @default.
• W2938397237 hasAuthorship W2938397237A5004234860 @default.
• W2938397237 hasAuthorship W2938397237A5006854305 @default.
• W2938397237 hasAuthorship W2938397237A5010869299 @default.
• W2938397237 hasAuthorship W2938397237A5019199940 @default.
• W2938397237 hasAuthorship W2938397237A5023686004 @default.
• W2938397237 hasAuthorship W2938397237A5060050668 @default.
• W2938397237 hasAuthorship W2938397237A5061926206 @default.
• W2938397237 hasAuthorship W2938397237A5064024738 @default.
• W2938397237 hasAuthorship W2938397237A5065836423 @default.
• W2938397237 hasAuthorship W2938397237A5071244438 @default.
• W2938397237 hasAuthorship W2938397237A5083774896 @default.
• W2938397237 hasAuthorship W2938397237A5086915181 @default.
• W2938397237 hasAuthorship W2938397237A5090359406 @default.
• W2938397237 hasBestOaLocation W29383972372 @default.
• W2938397237 hasConcept C126322002 @default.
• W2938397237 hasConcept C137183658 @default.
• W2938397237 hasConcept C15490471 @default.

• next